Quantum BioPharma Engages Stocks.news for Investor Relations Services
Quantum BioPharma Ltd. has hired Stocks.news for a six-month, $250,000 investor relations campaign, signaling its commitment to raising market awareness.
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company advancing therapies for neurodegenerative and metabolic disorders, announced it has engaged Stocks.news through IR Agency LLC for investor relations and consulting services. The six-month agreement, beginning June 8, 2026, includes company profile creation, media distribution, digital community development, news marketing and lead generation campaigns for a fee of US$250,000. IR Agency LLC is arm’s-length to Quantum and holds no direct or indirect equity interest in its securities, according to the company.
The move comes as Quantum continues to develop its pipeline, including Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models of multiple sclerosis, and its stake in Unbuzzd Wellness Inc., which markets UNBUZZD(TM) as an over-the-counter product. Quantum owns 19.84% of Unbuzzd (as of March 31, 2026) and is entitled to royalty payments of 7% of sales until total payments reach $250 million, after which the royalty drops to 3% in perpetuity. The company retains full rights to develop similar products for pharmaceutical and medical uses.
The investor relations engagement is designed to boost visibility among investors and the broader financial community, particularly as Quantum advances its drug candidates and navigates the commercialization of its assets. The company's newsroom at https://ibn.fm/QNTM provides updates on its progress.
Stocks.news, part of the IBN brand network, specializes in news distribution and investor awareness campaigns. The full press release is available at https://ibn.fm/iBZrw.
Quantum BioPharma's decision to invest $250,000 in investor relations underscores its focus on communicating its science and commercial milestones to the market. With multiple programs in development and a royalty stream from Unbuzzd, the company aims to build shareholder value while addressing significant medical needs.